UPDATE: JP Morgan Raises PT to $39 on Aegerion Pharmaceuticals on Encouraging Juxtapid Sales

JP Morgan maintained Aegerion Pharmaceuticals AEGR with an Overweight rating and raised the price target from $33.00 to $39.00. JP Morgan noted, "AEGR disclosed some encouraging Juxtapid (for HoFH) launch metrics as part of its 4Q update (financials were a non-event). 2013 guidance is unchanged for now (250-300 pts on drug; $15-$25M in net sales), but we suspect it may not stay that way for long. Eighty-five prescriptions were written in just the first 6 weeks of launch. Moreover, management commented that they anticipate steady “orphan like” growth throughout the year. Maintain OW." Aegerion Pharmaceuticals closed at $36.12 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsJP Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!